AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11826333 — intervention group
Group type: COMPARATOR
Intervention: Narrative review (author and journal concealed)
Number of subjects: 0
Study 11826333 — intervention group
Group type: COMPARATOR
Intervention: Narrative review (author and journal identified)
Number of subjects: 0
Study 10442958 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose propofol (2-2.5 mg x kg(‐1) bolus then 200 microg x kg(‐1) x min(‐1))
Number of subjects: 21
Study 10442958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose propofol (1-2.5 mg x kg(‐1) bolus then 100 microg x kg(‐1) x min(‐1))
Number of subjects: 21
Study 10442958 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0-2%)
Number of subjects: 21
Study 7771914 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.1 mg/kg)
Number of subjects: 34
Study 7771914 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.3 mg/kg)
Number of subjects: 34
Study 7771914 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.5 mg/kg)
Number of subjects: 34
Study 7771914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7771914 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 34
Study 2182939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic neurone blockade with debrisoquine for 4 weeks
Number of subjects: 38
Study 2182939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 375787 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRZ/HRZ regimen (6 months)
Number of subjects: 330
Study 375787 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRZ/HRZ regimen (4 months)
Number of subjects: 330
Study 375787 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRZ/HR regimen (6 months)
Number of subjects: 330
Study 375787 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRZ/HR regimen (4 months)
Number of subjects: 330
Study 375787 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bacilli resistant to isoniazid or streptomycin
Number of subjects: 330
Study 375787 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 330
Study 31699210 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lighting intervention
Number of subjects: 46
Study 28228427 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine
Number of subjects: 11648
Study 28228427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11648
Study 25867906 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic sepsis evaluation and management tool (218 patients)
Number of subjects: 407
Study 25867906 — intervention group
Group type: COMPARATOR
Intervention: Usual care (189 patients)
Number of subjects: 407
Study 24129463 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 1880
Study 24129463 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1880
Study 21415050 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg plus methotrexate (MTX)
Number of subjects: 619
Study 21415050 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg plus methotrexate (MTX)
Number of subjects: 619
Study 21415050 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 619
Study 19561422 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (Sub/MF59)
Number of subjects: 269
Study 19561422 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted split vaccine (split)
Number of subjects: 269
Study 17339550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose levels
Number of subjects: 31546
Study 17339550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose levels (adjusted for age, sex, smoking, previous myocardial infarction, hypertension, waist‐to‐hip ratio, creatinine, DM, and use of aspirin, beta‐blockers, or statins)
Number of subjects: 31546
Study 15230816 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily for 1 month, 200 microg twice daily for 5 months
Number of subjects: 60
Study 15230816 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) 10 mg three-times daily for 6 months
Number of subjects: 60
Study 11520335 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with curved lines
Number of subjects: 69
Study 11520335 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with straight lines
Number of subjects: 69
Study 11520335 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial evaluation test
Number of subjects: 69
Study 11520335 — intervention group
Group type: EXPERIMENTAL
Intervention: Final evaluation test after 2nd training session
Number of subjects: 69
Study 11520335 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 69
Study 10625576 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI patients with skin lesions during suprasystolic occlusion
Number of subjects: 53
Study 10625576 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 53
Study 10625576 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI patients with open venous ulcers
Number of subjects: 53
Study 10625576 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 53
Study 8904524 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil diet
Number of subjects: 60
Study 8904524 — intervention group
Group type: EXPERIMENTAL
Intervention: Betapol diet
Number of subjects: 60
Study 1864315 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of mifepristone (RU 486)
Number of subjects: 50
Study 6638543 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-N2O-O2 anesthesia
Number of subjects: 17
Study 6638543 — intervention group
Group type: COMPARATOR
Intervention: Thiopental-N2O-O2 anesthesia
Number of subjects: 17
Study 30566755 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Number Talk condition
Number of subjects: 47
Study 30566755 — intervention group
Group type: COMPARATOR
Intervention: Counting condition
Number of subjects: 47
Study 30007091 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive use during latest intercourse
Number of subjects: 1946
Study 30007091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to have children/more children
Number of subjects: 1946
Study 30007091 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-use of contraceptives among women not intending to have children
Number of subjects: 1946
Study 26038847 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg/day
Number of subjects: 23
Study 26038847 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 40 mg/day
Number of subjects: 23
Study 26038847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24887185 — intervention group
Group type: EXPERIMENTAL
Intervention: Linum usitatissimum L. (linseed) oil
Number of subjects: 100
Study 24887185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22113368 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group (TMG)
Number of subjects: 203
Study 22113368 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study 20599139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 17324009 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor plus G-CSF
Number of subjects: 50
Study 17324009 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor as a single mobilising agent
Number of subjects: 50
Study 17324009 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor in combination with G-CSF
Number of subjects: 50
Study 17324009 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor in combination with chemotherapy
Number of subjects: 50
Study 17324009 — intervention group
Group type: COMPARATOR
Intervention: G-CSF therapy alone
Number of subjects: 50
Study 16182156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 390
Study 16182156 — intervention group
Group type: COMPARATOR
Intervention: Codeine/acetaminophen 600/60 mg
Number of subjects: 390
Study 16182156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 11935151 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitors (specifically enalapril, n = 8)
Number of subjects: 39
Study 11935151 — intervention group
Group type: COMPARATOR
Intervention: Control (non-diabetic patients and patients without proliferative diabetic retinopathy, n = 8)
Number of subjects: 39
Study 11935151 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitors (enalapril, n = 8)
Number of subjects: 39
Study 10420105 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 43
Study 10420105 — intervention group
Group type: COMPARATOR
Intervention: Halothane/thiopental anesthesia
Number of subjects: 43
Study 7587232 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated porcine heparin (20 U/kg for ex vivo evaluation)
Number of subjects: 35
Study 7587232 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated porcine heparin (varying doses for in vitro evaluation)
Number of subjects: 35
Study 2406328 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 300 mg b.i.d.
Number of subjects: 242
Study 2406328 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 300 mg b.i.d.
Number of subjects: 242
Study 2406328 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 450 mg b.i.d.
Number of subjects: 242
Study 2406328 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 450 mg b.i.d.
Number of subjects: 242
Study 2406328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 242
Study 31621606 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) for ten weeks
Number of subjects: 40
Study 31621606 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 40
Study 30024661 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF‐EMF therapy
Number of subjects: 57
Study 30024661 — intervention group
Group type: COMPARATOR
Intervention: Control group (kinesiotherapy only)
Number of subjects: 57
Study 25669645 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (RA)
Number of subjects: 4006
Study 23263227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopy assistance
Number of subjects: 106
Study 23263227 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA without fluoroscopy
Number of subjects: 106
Study 22920798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) delivery of insulin lispro
Number of subjects: 22
Study 22920798 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) delivery of insulin lispro
Number of subjects: 22
Study 20022994 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical training
Number of subjects: 20
Study 20022994 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 20
Study 17592778 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention (permanent, independent housing with support services)
Number of subjects: 0
Study 17592778 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 0
Study 16311144 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potential (SSEP)
Number of subjects: 46
Study 16311144 — intervention group
Group type: COMPARATOR
Intervention: Electromyography and nerve conduction studies (EMG-NCS)
Number of subjects: 46
Study 16311144 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between SSEP and EMG-NCS
Number of subjects: 46
Study 12463582 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous hamstring graft
Number of subjects: 0
Study 12463582 — intervention group
Group type: COMPARATOR
Intervention: Patellar tendon graft
Number of subjects: 0
Study 9854758 — intervention group
Group type: EXPERIMENTAL
Intervention: titrated-dose oxycodone and sustained-release morphine sulfate
Number of subjects: 36
Study 9854758 — intervention group
Group type: EXPERIMENTAL
Intervention: set-dose oxycodone
Number of subjects: 36
Study 9854758 — intervention group
Group type: COMPARATOR
Intervention: naproxen only
Number of subjects: 36
Study 7875765 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity training
Number of subjects: 0
Study 7875765 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training
Number of subjects: 0
Study 7875765 — intervention group
Group type: COMPARATOR
Intervention: Control sedentary period
Number of subjects: 0
Study 2361891 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 6
Study 2361891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose, 5 mg/kg)
Number of subjects: 6
Study 2361891 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine plus cold exposure (5 degrees C for 2 h)
Number of subjects: 6
Study 44580 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 50
Study 44580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31056661 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year adjunction of AZA to glucocorticoids (GC)
Number of subjects: 50
Study 28099276 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injected in both submandibular and parotid glands
Number of subjects: 40
Study 28099276 — intervention group
Group type: COMPARATOR
Intervention: Control group (parotid injections only)
Number of subjects: 40
Study 26079801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet System (SSTS) 15 μg
Number of subjects: 419
Study 26079801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 23693018 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant DE combined with rh-endostatin (7.5 mg/m2, d1-d14, every 3 weeks)
Number of subjects: 68
Study 23693018 — intervention group
Group type: COMPARATOR
Intervention: neoadjuvant DE (docetaxel: 75 mg/m2, d1, epirubicin: 75 mg/m2, d1, every 3 weeks)
Number of subjects: 68
Study 23693018 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant DE combined with rh-endostatin
Number of subjects: 68
Study 23693018 — intervention group
Group type: COMPARATOR
Intervention: neoadjuvant DE
Number of subjects: 68
Study 21569445 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Care Management (DCM) intervention
Number of subjects: 320
Study 21569445 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 320
Study 18594954 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment
Number of subjects: 1015
Study 18594954 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance
Number of subjects: 1015
Study 15904632 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg intravenous bolus)
Number of subjects: 200
Study 15904632 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 200
Study 15904632 — intervention group
Group type: COMPARATOR
Intervention: Heparin (60 U/kg intravenous bolus)
Number of subjects: 200
Study 15904632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 200
Study 12610035 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (1.57 mg or 45 IU on each of the 2 dosing days in part 1; 4.7 mg or 135 IU in part 2)
Number of subjects: 45
Study 10498559 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (n = 55)
Number of subjects: 102
Study 10498559 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (n = 47)
Number of subjects: 102
Study 8607679 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood for 18 hours
Number of subjects: 120
Study 8607679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no autotransfusion)
Number of subjects: 120
Study 8607679 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood
Number of subjects: 120
Study 2006659 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (triamterene and hydrochlorothiazide)
Number of subjects: 840
Study 2006659 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics plus methyldopa
Number of subjects: 840
Study 2006659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840
Study 6161574 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental groups (3 of 4) involved in selecting topics and receiving feedback during the course
Number of subjects: 44
Study 6161574 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 6161574 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental groups (3 of 4)
Number of subjects: 44
Study 29794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1,300 mg/day
Number of subjects: 0
Study 29794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 0
Study 29794296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1,300 mg/day and 900 mg/day)
Number of subjects: 0
Study 28960739 — intervention group
Group type: EXPERIMENTAL
Intervention: Safewards intervention implemented in 13 wards for 12 weeks
Number of subjects: 44
Study 28960739 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of 31 wards with seclusion facilities
Number of subjects: 44
Study 26561613 — intervention group
Group type: EXPERIMENTAL
Intervention: UNIMMAP (multiple micronutrient preparation)
Number of subjects: 1156
Study 26561613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1156
Study 22769574 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 20
Study 22769574 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 20
Study 20869928 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical tocotrienol
Number of subjects: 122
Study 20869928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 18230197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 3
Study 16740175 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 251
Study 16740175 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 251
Study 15231900 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 group (antibiotic therapy when IL-8 >70 pg/mL and/or CRP >10 mg/L)
Number of subjects: 1291
Study 15231900 — intervention group
Group type: COMPARATOR
Intervention: Standard group (antibiotic therapy according to the guidelines of each center)
Number of subjects: 1291
Study 15231900 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 group
Number of subjects: 1291
Study 15231900 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 1291
Study 11702799 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Advice (BA)
Number of subjects: 301
Study 11702799 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement (ME)
Number of subjects: 301
Study 11702799 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 301
Study 9221708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once daily)
Number of subjects: 100
Study 9221708 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg once daily)
Number of subjects: 100
Study 8133796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg every 3 weeks for 18 months)
Number of subjects: 46
Study 8133796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 8133796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 46
Study 3628442 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg diazepam
Number of subjects: 16
Study 3628442 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.14 mg/kg diazepam
Number of subjects: 16
Study 3628442 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.21 mg/kg diazepam
Number of subjects: 16
Study 3628442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31657840 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace SSB sales ban
Number of subjects: 214
Study 31657840 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 214
Study 31657840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brief intervention)
Number of subjects: 214
Study 31657840 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in SSB intake
Number of subjects: 214
Study 29553444 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate safety culture
Number of subjects: 640
Study 29553444 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital management support
Number of subjects: 640
Study 29553444 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-punitive response to errors
Number of subjects: 640
Study 29553444 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication and feedback on errors
Number of subjects: 640
Study 29553444 — intervention group
Group type: EXPERIMENTAL
Intervention: Teamwork
Number of subjects: 640
Study 29553444 — intervention group
Group type: EXPERIMENTAL
Intervention: Organisational learning
Number of subjects: 640
Study 29553444 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervisor actions promoting patient safety
Number of subjects: 640
Study 26244263 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized tray during bleaching procedure
Number of subjects: 46
Study 26244263 — intervention group
Group type: COMPARATOR
Intervention: Bleaching techniques (with and without tray)
Number of subjects: 46
Study 24950773 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic through MOTAP catheters
Number of subjects: 120
Study 24950773 — intervention group
Group type: COMPARATOR
Intervention: Normal saline through MOTAP catheters (placebo)
Number of subjects: 120